Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

• Astorgues-Xerri L Oncology Therapeutic Development, Clichy, France.
• Vázquez R Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.
• Odore E RadioPharmacology Department, Curie Institute-Rene Huguenin Hospital, Saint Cloud, France.
• Rezai K RadioPharmacology Department, Curie Institute-Rene Huguenin Hospital, Saint Cloud, France.
• Kahatt C Oncology Therapeutic Development, Clichy, France.
• Mackenzie S Oncology Therapeutic Development, Clichy, France.
• Bekradda M Oncology Therapeutic Development, Clichy, France.
• Coudé MM Laboratoire de Transfert des Leucémies, Université Paris Diderot, Paris, France.
• Dombret H Laboratoire de Transfert des Leucémies, Université Paris Diderot, Paris, France.
• Gardin C Laboratoire de Transfert des Leucémies, Université Paris Diderot, Paris, France.
• Lokiec F RadioPharmacology Department, Curie Institute-Rene Huguenin Hospital, Saint Cloud, France.
• Raymond E Medical Oncology Department, CHUV, Lausanne, Switzerland.
• Noel K Oncoethix SA, Lucerne, Switzerland.
• Cvitkovic E Oncoethix SA, Lucerne, Switzerland.
• Herait P Oncoethix SA, Lucerne, Switzerland.
• Bertoni F Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.
• Riveiro ME Oncology Therapeutic Development, Clichy, France.

Show more…

Acetanilides

Animals

Antineoplastic Agents

Apoptosis

Biomarkers, Tumor

Cell Cycle

Cell Line, Tumor

Disease Models, Animal

Drug Synergism

Heterocyclic Compounds, 3-Ring

Humans

Mice

Mutation

Proteins

Xenograft Model Antitumor Assays